The pulsatile component of left atrial pressure has little effect on pulmonary artery impedance estimation in normal

Masafumi Fukumitsu1,2, Toru Kawada1, Shuji Shimizu1

  • 1Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, Japan.

Physiological Reports
|December 18, 2018
PubMed

Related Concept Videos

Normal and Tangetial Components: Problem Solving01:24

Normal and Tangetial Components: Problem Solving

Consider a man with a mass of 70 kg seated in a chair connected to a pin support through a member BC. If the man maintains an upright position, the task is to determine the horizontal and vertical reactions of the chair on the man when the member makes a 45° angle with the horizontal. At this moment, the man has a speed of 5 m/s, increasing at a rate of 1 m/s².
602
Curvilinear Motion: Normal and Tangential Components01:27

Curvilinear Motion: Normal and Tangential Components

When a car traverses a curved road, its motion can be elucidated by breaking it down into tangential and normal components. The car-centric coordinates attached to the vehicle move with it.
The positive direction of the t-axis aligns with the increasing position of the car along the curved path, denoted by the unit vector ut. Simultaneously, the n-axis, perpendicular to the t-axis, dissects the curved path into differential arc segments, each forming the arc of a circle with a radius of...
960
Equations of Motion: Normal and Tangetial Components01:10

Equations of Motion: Normal and Tangetial Components

Describing the motion of a particle along a curvilinear path involves understanding its components in terms of normal and tangential aspects. The normal component aligns with the radial direction of the curve at a specific point, reflecting changes in the trajectory of the velocity vector. In contrast, the tangential component is tangential to the curve at that point and signifies the rate at which speed alters along the path.
Newton's second law of motion is employed to articulate the...
1.2K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
601
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
467
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
508